BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 1983054)

  • 21. Vasodilatory action of carvedilol.
    Sponer G; Strein K; Bartsch W; Müller-Beckmann B
    J Cardiovasc Pharmacol; 1992; 19 Suppl 1():S5-11. PubMed ID: 1378150
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of low dose beta blockers on atrial and ventricular (B type) natriuretic factor in heart failure: a double blind, randomised comparison of metoprolol and a third generation vasodilating beta blocker.
    Sanderson JE; Chan WW; Hung YT; Chan SK; Shum IO; Raymond K; Woo KS
    Br Heart J; 1995 Nov; 74(5):502-7. PubMed ID: 8562234
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A rest and exercise haemodynamic evaluation of a new cardio-selective beta-adrenoceptor blocker celiprolol alone and in combination with nitroglycerine in ischaemic heart disease.
    Silke B; Verma SP; Frais MA; Reynolds G; Taylor SH
    Br J Clin Pharmacol; 1986 Dec; 22(6):697-706. PubMed ID: 2882772
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of carvedilol in patients with impaired left ventricular function due to ischaemic heart disease.
    Lahiri A; Rodrigues EA; DasGupta P; Jain D; van der Does R; Raftery EB
    Z Kardiol; 1989; 78 Suppl 3():21-7. PubMed ID: 2573213
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sympathetic activation and the role of beta-blockers in chronic heart failure.
    Krum H
    Aust N Z J Med; 1999 Jun; 29(3):418-27. PubMed ID: 10868514
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vasodilating beta-blockers in heart failure.
    Raftery EB
    Eur Heart J; 1995 Jul; 16 Suppl F():32-7. PubMed ID: 8521882
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Carvedilol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.
    McTavish D; Campoli-Richards D; Sorkin EM
    Drugs; 1993 Feb; 45(2):232-58. PubMed ID: 7681374
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Renal and cardiac function during alpha1-beta-blockade in congestive heart failure.
    Heitmann M; Davidsen U; Stokholm KH; Rasmussen K; Burchardt H; Petersen EB
    Scand J Clin Lab Invest; 2002; 62(2):97-104. PubMed ID: 12004934
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tolerability of beta-blockers in outpatients with refractory heart failure who were receiving continuous milrinone.
    Earl GL; Verbos-Kazanas MA; Fitzpatrick JM; Narula J
    Pharmacotherapy; 2007 May; 27(5):697-706. PubMed ID: 17461705
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A review of the animal pharmacology of labetalol, a combined alpha- and beta-adrenoceptor-blocking drug.
    Brittain RT; Levy GP
    Br J Clin Pharmacol; 1976 Aug; 3(4 Suppl 3):681-4. PubMed ID: 10948
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial.
    Jabbour A; Macdonald PS; Keogh AM; Kotlyar E; Mellemkjaer S; Coleman CF; Elsik M; Krum H; Hayward CS
    J Am Coll Cardiol; 2010 Apr; 55(17):1780-7. PubMed ID: 20413026
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The vasodilatory beta-blockers.
    Pedersen ME; Cockcroft JR
    Curr Hypertens Rep; 2007 Aug; 9(4):269-77. PubMed ID: 17686376
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of pharmacodynamics between carvedilol and metoprolol in rats with isoproterenol-induced cardiac hypertrophy: effects of carvedilol enantiomers.
    Hanada K; Asari K; Saito M; Kawana J; Mita M; Ogata H
    Eur J Pharmacol; 2008 Jul; 589(1-3):194-200. PubMed ID: 18534575
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Myocardial protection by the novel vasodilating beta-blocker, carvedilol: potential relevance of anti-oxidant activity.
    Feuerstein GZ; Yue TL; Cheng HY; Ruffolo RR
    J Hypertens Suppl; 1993 Jun; 11(4):S41-8. PubMed ID: 8104241
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Acute and chronic hemodynamic effects of drugs with different actions on adrenergic receptors: a comparison between alpha blockers and different types of beta blockers with and without vasodilating effect.
    Lund-Johansen P; Omvik P
    Cardiovasc Drugs Ther; 1991 Jun; 5(3):605-15. PubMed ID: 1678963
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative cardiac haemodynamics of bisoprolol, celiprolol, carvedilol and nebivolol in normal volunteers.
    De Cree J; Van Nueten L; Geukens H; Verhaegen H
    Int J Clin Pharmacol Res; 1992; 12(4):159-63. PubMed ID: 1363660
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Haemodynamic effects of new beta-blockers with vasodilatory properties in essential hypertension.
    Tsukiyama H; Otsuka K; Horii M
    Drugs; 1988; 36 Suppl 6():48-54. PubMed ID: 2908304
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hemodynamic effects of beta-blocking compounds possessing vasodilating activity: a review of labetalol, prizidilol, and dilevalol.
    Lund-Johansen P
    J Cardiovasc Pharmacol; 1988; 11 Suppl 2():S12-7. PubMed ID: 2464093
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An overview of the pharmacodynamic properties and therapeutic potential of combined alpha- and beta-adrenoceptor antagonists.
    van Zwieten PA
    Drugs; 1993 Apr; 45(4):509-17. PubMed ID: 7684671
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cardioprotective effects of carvedilol, a novel beta adrenoceptor antagonist with vasodilating properties, in anaesthetised minipigs: comparison with propranolol.
    Bril A; Slivjak M; DiMartino MJ; Feuerstein GZ; Linee P; Poyser RH; Ruffolo RR; Smith EF
    Cardiovasc Res; 1992 May; 26(5):518-25. PubMed ID: 1359930
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.